Drug Interaction:
Ciclosporin, tacrolimus , rifampicin, efavirenz, nevirapine, dexamethasone, phenytoin,
carbamazepine, Glucose incompatibility
Indication:
Treatment of invasive candidiasis
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Caspofungin Antibiotic & Merck & Co 16-03-2013
Antifungals
New drugs approved For Marketing by Drug Controller General of India(DCGI )
during the period January 1988 to November 2014
(Ref- IDMA Annual Publication 2015)
Name of Drug Indication Date of Approval
Caspofungin acetate injection 31-01-2009
Addl.Indication
For use in following-
i. Empirical therapy for presumed fungal infections in febrile neurotropenic
patients
ii. Treatment of candidema and the following canida infections - intra-abdominal
abcesses , peritonitis, and pleural space infections
iii. Treatment of esophageal candidiasis
iv. Treatment of invasive aspergil-losis in patients who are refractory to or
intolerant of other therapies ie. amphotericin B, Lipid formulations of
Amphotericin B and/or Itraconazole)
Adverse Reaction:
Inj site reaction, headache, dyspnoea, angioedema,
brochospasm, GI upset, rash, fever,
pruritus, chills, arthralgia, hypertension, tachycardia,
raised liver enzyme, decreased haemotocrit,
hypokalaemia, hypoalbuminaemia
Children- also hypotension
Contra-Indications:
Hepatic impairment in children
severe hepatic impairment in adults
Lactation
Special Precaution-
Moderate hepaticimpairment in adults.
Monitor liver function tests
Pregnancy
Dosages/ Overdosage Etc:
Indication
Treatment of invasive candidiasis
Dosage-
Adults- reconstitute and dilute soln before administration by slow i,v. ing over 1 hour
Under 80kg- initially 70mg on Day 1 then 50mg daily
Over 80kg - 70mg daily
Continue treatment for 14 days after last positive culture and of invasive aspergillosis for 7 days
after resolution of symptoms
Empirical therapy should continue up to 72 hours after resolution of neutropenia
If fungal infection is confirmed treat for a min period of 14 days and for at least 7 days after both neutropenia and clinical symptoms resolve
Children -reconsittute and dilute soln. before administering by slow i.v. inf over 1 hour
Under 3 mths not recommended
3 months - 70mg/m2 on Day 1 then 50mg/m2 daily if required Max 70mg/m2 daily
Duration of treatment as adults
Pregnancy and lactation:
Use contraindicated. Observe caution if required to be administered.
Manufacturer Details